http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1919908-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 |
filingDate | 2006-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09271a040d18ccfe6dfb2a7e4b3ac74e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6302b7bf4bd9c5e1490cb590114d2943 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3b89a0df7bc3f25707a51f76f9223ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a372083a1237b043b34bed197ba37f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd5c00aefa4972cf99962c3106833972 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43cbc2852e7a503d967a0b2e3969174d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a4764ecb22cbf3aa7022ed6ee491225 |
publicationDate | 2008-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1919908-A1 |
titleOfInvention | Triazole derivatives as modulators of dopamine d3 receptors |
abstract | The present invention relates to novel compounds of formula (I) or a salt thereof: wherein: G is a 5- or 6-membered heteroaromatic group, or is a 9- or 10-membered bicyclic heteroaromatic group containing one or two heteroatoms independently selected from nitrogen and oxygen, wherein G is not pyridyl, indazolyl or benzothiazolyl; p is an integer ranging from 0 to 4; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl or SF5; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; n is 2 or 3; X is S or -CH2-; R3 is C1-4alkyl; R4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl; R5 is isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl or 2-pyrrolidinonyl, wherein each group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat substance related disorders, as antipsychotic agents, premature ejaculation or cognition impairment. |
priorityDate | 2005-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 552.